Henry Schein Valuation
Is H1SI34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of H1SI34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: H1SI34 (R$209.09) is trading below our estimate of fair value (R$444.52)
Significantly Below Fair Value: H1SI34 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for H1SI34?
Key metric: As H1SI34 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is H1SI34's PE Ratio? | |
|---|---|
| PE Ratio | 30.8x |
| Earnings | US$314.00m |
| Market Cap | US$9.68b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.1x |
| Enterprise Value/EBITDA | 15.2x |
| PEG Ratio | 1.2x |
Price to Earnings Ratio vs Peers
How does H1SI34's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.8x | ||
PFRM3 Profarma Distribuidora de Produtos Farmacêuticos | 7.8x | n/a | R$866.9m |
RDOR3 Rede D'Or São Luiz | 17x | 17.8% | R$62.9b |
ODPV3 Odontoprev | 10.8x | 3.7% | R$5.8b |
FLRY3 Fleury | 11.8x | 13.9% | R$7.4b |
H1SI34 Henry Schein | 30.8x | 26.7% | R$9.7b |
Price-To-Earnings vs Peers: H1SI34 is expensive based on its Price-To-Earnings Ratio (30.8x) compared to the peer average (11.8x).
Price to Earnings Ratio vs Industry
How does H1SI34's PE Ratio compare vs other companies in the Global Healthcare Industry?
| 12 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 12 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: H1SI34 is expensive based on its Price-To-Earnings Ratio (30.8x) compared to the Global Healthcare industry average (20.9x).
Price to Earnings Ratio vs Fair Ratio
What is H1SI34's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 30.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate H1SI34's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Teladoc Health
US$2.0b
Provides virtual healthcare services worldwide.
T2DH34
US$2.37
7D
17.9%
1Y
-20.5%
CM Hospitalar S/A
R$644.2m
Engages in the distribution of hospital materials, medicines, and nutrition products in Brazil.
VVEO3
R$1.94
7D
1.6%
1Y
-86.1%
Centene
US$30.3b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
C1NC34
US$353.30
7D
0.9%
1Y
-3.3%